Vaxcyte Inc Market Cap ($9.23 Billion)
Market Cap & Net Worth: Vaxcyte Inc (PCVX)
Vaxcyte Inc market cap. Vaxcyte Inc (NASDAQ:PCVX) has a market capitalization of $9.23 Billion ($9.23 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2296 globally and #861 in its home market, demonstrating a -1.30% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vaxcyte Inc's stock price $62.03 by its total outstanding shares 148805278 (148.81 Million). Also see PCVX cash flow conversion for how efficiently the company converts equity into cash flow.
Vaxcyte Inc Market Cap History (2020–2026)
Vaxcyte Inc market cap history from 2020 to 2026. Data shows growth from $3.95 Billion to $9.23 Billion (14.48% CAGR). Check PCVX stock price for real-time trading data and today's change.
Index Memberships
Vaxcyte Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.35% | #48 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.02% | #264 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.50% | #31 of 263 |
Weight: Vaxcyte Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vaxcyte Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vaxcyte Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Vaxcyte Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PCVX by Market Capitalization
Companies near Vaxcyte Inc in the global market cap rankings as of November 1, 2026. Also see PCVX total assets for a full breakdown of the balance sheet.
Key companies related to Vaxcyte Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Vaxcyte Inc (2020–2026)
Market capitalization of Vaxcyte Inc from 2020 to today. Between 2020 and today, Vaxcyte Inc's market cap moved from $3.95 Billion to $ 9.23 Billion, with a yearly change of 14.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.23 Billion | +34.44% |
| 2025 | $6.87 Billion | -43.64% |
| 2024 | $12.18 Billion | +30.35% |
| 2023 | $9.34 Billion | +30.97% |
| 2022 | $7.14 Billion | +101.56% |
| 2021 | $3.54 Billion | -10.46% |
| 2020 | $3.95 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Vaxcyte Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.23 Billion USD |
| MoneyControl | $9.23 Billion USD |
| MarketWatch | $9.23 Billion USD |
| marketcap.company | $9.23 Billion USD |
| Reuters | $9.23 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrie… Read more